Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Authorization Observational Study of Biktarvy in HIV-1-Infected Patients in China
ChiCTR2100042380Phase 4Completed
- Sponsor
- Guangzhou Eighth People's Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Guangzhou Eighth People's Hospital. Primary endpoints: Incidence of adverse events and serious adverse events and HIV-1 RNA suppression at 12 months. Started Nov 2020; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR2100042380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042380.